Search Result

Results for "

Synuclein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	α-synuclein (79) Amino Acid Derivatives (1) Amyloid-β (7) Apoptosis (12) Autophagy (14) Bcl-2 Family (5) Beclin1 (1) Caspase (1) DNA/RNA Synthesis (2) Drug Metabolite (1) DYRK (2) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) Fluorescent Dye (2) Fungal (2) GLP Receptor (5) Glycosidase (1) Insulin Receptor (5) Isotope-Labeled Compounds (3) Mitosis (3) Monoamine Oxidase (3) Necroptosis (1) NF-κB (1) Nuclear Hormone Receptor 4A/NR4A (1) OGA (1) p38 MAPK (5) Parasite (2) PROTACs (1) Proteasome (1) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (2) Reference Standards (6) RIP kinase (1) Sirtuin (1) Tau Protein (2)
By Research Areas:	Cancer (19) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (10) Metabolic Disease (8) Neurological Disease (95)

By Targets:

α-synuclein (79)

Amino Acid Derivatives (1)

Amyloid-β (7)

Apoptosis (12)

Autophagy (14)

Bcl-2 Family (5)

Beclin1 (1)

Caspase (1)

DNA/RNA Synthesis (2)

Drug Metabolite (1)

DYRK (2)

E3 Ligase Ligand-Linker Conjugates (1)

Endogenous Metabolite (1)

Fluorescent Dye (2)

Fungal (2)

GLP Receptor (5)

Glycosidase (1)

Insulin Receptor (5)

Isotope-Labeled Compounds (3)

Mitosis (3)

Monoamine Oxidase (3)

Necroptosis (1)

NF-κB (1)

Nuclear Hormone Receptor 4A/NR4A (1)

OGA (1)

p38 MAPK (5)

Parasite (2)

PROTACs (1)

Proteasome (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (6)

RIP kinase (1)

Sirtuin (1)

Tau Protein (2)

By Research Areas:

Cancer (19)

Cardiovascular Disease (2)

Infection (4)

Inflammation/Immunology (10)

Metabolic Disease (8)

Neurological Disease (95)

103

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

*α-Synuclein* (61-75) TFA**	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

*α-Synuclein* 4554W**	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

*α-Synuclein* (61-75)**	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

*α-Synuclein* (34-45) (human)**	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

*α-Synuclein* (45-54) (human)**	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

*α-Synuclein* (71-82) (human)**	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

*α-Synuclein* inhibitor 9**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 9 (Compound 20C) is an *α-Synuclein* inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .

*tau Protein/α-synuclein-IN-1*	α-synuclein	Neurological Disease
tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and *α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein*-IN-1 can be used in study Alzheimer’s disease .

*α-Synuclein* inhibitor 8**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 8 is an active inhibitor of *α-Synuclein* with an IC₅₀ value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity .

*α-Synuclein* (67-78) (human)**	α-synuclein	Neurological Disease
α-Synuclein (67-78) (human) is the 67-78 fragment of *α-Synuclein. α-Synuclein* (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake .

*α-Synuclein* inhibitor 3**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 3 (Compound 7g) is a *α-synuclein* (α -Syn)** aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .

*Dyrk1A/α-synuclein-IN-2*	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and *α-synuclein* aggregation inhibitor with an IC₅₀** of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect .

*α-Synuclein* modulator 1**	α-synuclein	Neurological Disease
α-Synuclein modulator 1 (Compound 7k) is a modulator for *α-synuclein. α-Synuclein* modulator 1 exhibits a maximal absorption and emission wavelength of 386 and 603 nm in ACN/PBS (1:1) buffer .

*tau Protein/α-synuclein-IN-2*	α-synuclein	Neurological Disease
Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and α-syn inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces α-syn oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.

*α-Synuclein* (61-95) (human)**	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

*α-Synuclein* inhibitor 13**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .

*α-Synuclein* aggregate binder 1**	Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for *α-synuclein* aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with ¹⁸F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .

*PROTAC α-synuclein* degrader 3**	PROTACs α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 3 (Compound 5) is a selective *α-synuclein* PROTAC degrader. PROTAC α-synuclein degrader 3 can promote the ubiquitination and degradation of α-synuclein. PROTAC α-synuclein degrader 3 can be used for Parkinson's disease research (Pink: target protein ligand (HY-W278021); Black: linker; HY-133302; Blue: E3 ligase VHL ligand (HY-112078)) .

*α-Synuclein* inhibitor 11**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 11 (compound 1) is a selective *α-synuclein* (α-syn) oligomer formation** inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .

*α-Synuclein* inhibitor 12**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases .

*α-Synuclein* (61-95) (human) TFA**	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

*PROTAC α-synuclein* degrader 5**	α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 5 is a highly selective small-molecule degraders (PROTAC) of *α-synuclein* aggregates, with an DC₅₀ of 7.51 μM and the highest degradation rate D_max of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research .

*Dyrk1A/α-synuclein-IN-1*	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and *α-synuclein* aggregation inhibitor with IC₅₀** values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect .

*α-Synuclein* inhibitor 10**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

*α-Synuclein* inhibitor 6**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of *α-Synuclein* (α-Syn) aggregation, with an IC₅₀** of 1.70 μM and inhibition ratio at 30 μM of 94.4% .

*α-Synuclein* inhibitor 4**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of *α-Synuclein* (α-Syn) aggregation, with an IC₅₀** of 0.98 μM and inhibition ratio at 30 μM of 91.2% .

*α-Synuclein* inhibitor 7**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of *α-Synuclein* (α-Syn) aggregation, with an IC₅₀** of 1.95 μM and inhibition ratio at 30 μM of 85.8% .

*α-Synuclein* inhibitor 5**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of *α-Synuclein* (α-Syn) aggregation, with an IC₅₀** of 1.22 μM and inhibition ratio at 30 μM of 94.3% .

*PROTAC α-synuclein* degrader 6**	α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 6 (compound T3) is a PROTAC degrader of *α-synuclein* and tau, with EC₅₀ of 1.57 μM and 4.09 μM, respectively. PROTAC α-synuclein degrader 6 plays an important role in neurodegenerative diseases (NDs) research (Blue:ubiquitin E3 ligase cereblon ligand (HY-14658), Black: linker (HY-128803); Pink: Ligand for target protein (HY-151035)) .

MODAG-001	Fluorescent Dye	Neurological Disease
MODAG-001 can bind to synuclein fibrils in a rat brain. MODAG-001 is a candidate α-syn imaging probe .

Cinpanemab BIIB054; Anti-Alpha-Synuclein Reference Antibody (cinpanemab)	α-synuclein	Neurological Disease
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to *α-synuclein*. Cinpanemab can be used for the research of Parkinson's disease .

Corynoxine 1 Publications Verification	Autophagy	Neurological Disease Cancer
Corynoxine, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria rhynchophylla. Corynoxine is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

Corynoxine hydrochloride	Autophagy	Neurological Disease Cancer
Corynoxine hydrochloride, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria macrophylla. Corynoxine hydrochloride is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

Sycosterol A	α-synuclein	Neurological Disease
Sycosterol A is a sterol-based *α-synuclein* (α-syn)** inhibitor that targets α-synuclein aggregates and inhibits α-synuclein aggregation. Sycosterol A can be used in the study of anti-neurodegenerative diseases .

Dopal	α-synuclein	Neurological Disease
Dopal is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal can generate reactive oxygen species (ROS), and triggers aggregation of *α-synuclein. Dopal elicits α-synuclein* accumulation and hampers α-synuclein clearance in primary neurons .

Dopal (purity>80%)	α-synuclein	Neurological Disease
Dopal (purity>80%) is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal (purity>80%) can generate reactive oxygen species (ROS), and triggers aggregation of *α-synuclein. Dopal (purity>80%) elicits α-synuclein* accumulation and hampers α-synuclein clearance in primary neurons .

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an *α-synuclein* knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .

Corynoxine B 3 Publications Verification	α-synuclein	Neurological Disease Cancer
Corynoxine B is an alkaloid-based autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .

Aerophobin-2	α-synuclein	Neurological Disease
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of *α-synuclein* (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

ELN484228	α-synuclein	Neurological Disease
ELN484228 is a blocker of *α-synuclein* which is a key protein in Parkinson’s disease.

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an inhibitor of *α-synuclein* and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

(S)-Minzasolmin (S)-UCB0599; (S)-NPT200-11	α-synuclein	Neurological Disease
(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .

Brazilin-7-acetate	α-synuclein	Metabolic Disease
Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease .

Synucleozid NSC 377363	DNA/RNA Synthesis	Neurological Disease
Synucleozid (NSC 377363) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein. Synucleozid selectively targets the *α-synuclein* mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

Corynoxine B (Standard)	α-synuclein Reference Standards	Neurological Disease Cancer
Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice .

Synucleozid hydrochloride NSC 377363 hydrochloride	DNA/RNA Synthesis	Neurological Disease
Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the?SNCA?mRNA?that encodes α-synuclein protein. Synucleozid selectively?targets the?α-synuclein?mRNA 5′ UTR at the designed IRE site, decreases the amount of?SNCA?mRNA loaded into polysomes and thereby inhibits?SNCA?translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library

1,693 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,693 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Cat. No.	Product Name	Type

HY-D1443

BSB (trans,trans)-1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene	Fluorescent Dyes/Probes
BSB is a Congo red-derived fluorescent probe. BSB binds not only to extracellular amyloid β protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins. BSB acts as a prototype imaging agent for Alzheimer's disease .

HY-D0914

Fast Green FCF

FD&C Green No. 3; Food green 3; C.I. 42053

Dyes

Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-114118F

Semaglutide, FITC labeled

Fluorescent Dyes/Probes

Semaglutide, FITC labeled is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-D0914A

Fast green FCF free acid

Dyes

Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

Cat. No.	Product Name	Target	Research Area

HY-P3140A

*α-Synuclein* (61-75) TFA**	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P5082

*α-Synuclein* 4554W**	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-P4704A

*α-Synuclein* (61-95) (human) TFA**	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P3140

*α-Synuclein* (61-75)**	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P5041

*α-Synuclein* (34-45) (human)**	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-P5044

*α-Synuclein* (45-54) (human)**	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5046

*α-Synuclein* (71-82) (human)**	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5043

*α-Synuclein* (67-78) (human)**	α-synuclein	Neurological Disease
α-Synuclein (67-78) (human) is the 67-78 fragment of *α-Synuclein. α-Synuclein* (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake .

HY-P4704

*α-Synuclein* (61-95) (human)**	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P5106

*α-Synuclein* (32-37) (human)**	Peptides	Others
α-Synuclein (32-37) (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10360

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an *α-synuclein* knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
PDpep1.3 is a peptide inhibitor of *α-synuclein* that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .

HY-P10844

ANK peptide	Amino Acid Derivatives	Cancer
ANK peptide is a novel peptide designed based on the conserved residues of single ankyrin motif. ANK peptide is a synuclein-γ (SNCG) inhibitor that binds to SNCG and competes with SNCG-BubR1 interaction to enhance the sensitivity of breast cancer cells to antimicrotubule drugs such as nocodazole and paclitaxel. ANK peptide can be used in the study of cancer .

HY-114118

Semaglutide Maximum Cited Publications 18 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118B

Semaglutide acetate Maximum Cited Publications 18 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 18 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118F

Semaglutide, FITC labeled	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide, FITC labeled is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Product Name	Target	Research Area

HY-P99356

Cinpanemab BIIB054; Anti-Alpha-Synuclein Reference Antibody (cinpanemab)	α-synuclein	Neurological Disease
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to *α-synuclein*. Cinpanemab can be used for the research of Parkinson's disease .

HY-P99405

Prasinezumab PRX 002; RG 7935; RO 7046015	α-synuclein	Neurological Disease
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated *α-synuclein*. Prasinezumab has the potential for Parkinson's disease research .

Species:	Human (12) Mouse (2) Cynomolgus (1)
Tag:	His (8) Tag Free (6) Avi (1) Fc (1)
Source:	HEK293 (2) E. coli (13)

Cat. No.	Compare	Product Name	Species	Source

HY-P70660

	SNCA Protein, Mouse Alpha-Synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Snca	Mouse	E. coli
	SNCA proteins are critical for synaptic activity and regulate vesicle trafficking and neurotransmitter release. As a monomer, it enhances the vesicle exocytosis process. SNCA Protein, Mouse is the recombinant mouse-derived SNCA protein, expressed by E. coli , with tag free.

HY-P71043

	SNCG Protein, Human Gamma-Synuclein; Breast Cancer-Specific Gene 1 Protein; Persyn; Synoretin; SR; SNCG; BCSG1; PERSYN; PRSN	Human	E. coli
	SNCG proteins help maintain the integrity of neurofilament networks and may influence axonal structure during development and adulthood. In vitro, it enhances the sensitivity of neurofilament-H to calcium-dependent proteases. SNCG Protein, Human is the recombinant human-derived SNCG protein, expressed by E. coli , with tag free.

HY-P70577

	SNCA Protein, Human Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	SNCA Protein is a protein abnormally aggregated to form Lewy bodies. SNCA Protein causes neuronal differentiation and maturation disorders, inhibits neurite outgrowth, reduces neuronal electrical activity through increased gene copy number (such as triploidy) or mutation, and promotes the release of extracellular toxic particles (such as oligomers) by interfering with the autophagy-lysosomal pathway (ALP), thereby inducing inflammatory responses and damage to neighboring cells. SNCA Protein, Human is a recombinant SNCA protein expressed by E. coli without a tag.

HY-P71327

	SNCA Protein, Human (His) Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human (His) is the recombinant human-derived SNCA protein, expressed by E. coli , with N-6*His labeled tag.

HY-P702985

	SNCB Protein, Human (His) Beta-Synuclein; SNCB	Human	E. coli
	SNCB Protein, Human (His) is the recombinant human-derived SNCB, expressed by E. coli , with His labeled tag. ,

HY-P705391

	SNCA Protein, Cynomolgus (His) Alpha-Synuclein; SNCA	Cynomolgus	E. coli

HY-P78805

	SNCA Protein, Human (Biotinylated, HEK293, His-Avi) SNCA; NACP; PARK1; alpha-Synuclein	Human	HEK293
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SNCA protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P704896

	SNCA Protein, Mouse (His) Alpha-Synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Snca	Mouse	E. coli

HY-P704889

	SNCA Protein, Human (HEK293, Fc) Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	HEK293

HY-P704891

	SNCA Protein, Human (A53T) Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704892

	SNCA Protein, Human (E46K) Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704894

	SNCA Pre-formed Fibrils Protein, Human Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704890

	SNCA Protein, Human (A53T, His) Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704893

	SNCA Pre-formed Fibrils Protein, Human (His) Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704895

	SNCA Pre-formed Fibrils Protein, Human (A53T, His) Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-Y0790S

Cuminaldehyde-d8
Cuminaldehyde-d8 is deuterated labeled Cuminaldehyde (HY-Y0790). Cuminaldehyde is the major component of Cuminum cyminum, a natural aldehyde with inhibitory effect on alpha-synuclein fibrillation and cytotoxicity. Cuminaldehyde shows anticancer activity .

HY-W707693

Scyllo-Inositol-d6

Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82328

	*alpha Synuclein* Antibody (YA2073)** 1 Publications Verification SNCA; NACP; PARK1; Alpha-Synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, IHC-P, IP	Human, Rat
	alpha Synuclein Antibody (YA2073) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2073), targeting alpha Synuclein, with a predicted molecular weight of 14 kDa (observed band size: 18 kDa). alpha Synuclein Antibody (YA2073) can be used for WB, IHC-P, IP experiment in human, rat background.

HY-P81739

	*Phospho-alpha Synuclein* (Ser129) Antibody (YA1484)** SNCA; NACP; PARK1; Alpha-Synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, ICC/IF	Human, Mouse, Rat
	Phospho-alpha Synuclein (Ser129) Antibody (YA1484) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1484), targeting Phospho-alpha Synuclein (Ser129), with a predicted molecular weight of 14 kDa. Phospho-alpha Synuclein (Ser129) Antibody (YA1484) can be used for WB, ICC/IF experiment in human, mouse, rat background.

HY-P85381

	Synuclein-γ Antibody (YA5073) SNCG; BCSG1; PERSYN; PRSN; Gamma-Synuclein; Breast cancer-specific gene 1 protein; Persyn; Synoretin; SR	WB, IHC-P, ICC/IF, ELISA	Human
	Synuclein-γ Antibody (YA5073) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Synuclein-γ. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human.

HY-P85380

	Synuclein-α Antibody (YA5072) SNCA; NACP; PARK1; Alpha-Synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, IHC-P, ICC/IF, ELISA	Human
	Synuclein-α Antibody (YA5072) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Synuclein-α. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human.

HY-P86127

	Synuclein-α Antibody (YA5819) SNCA; NACP; PARK1; Alpha-Synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Synuclein-α Antibody (YA5819) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Synuclein-α. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.

HY-P83254

	*alpha/beta Synuclein* Antibody (YA2999)** alpha Synuclein; beta Synuclein; NACP; PD1; SNCA; SNCB	WB, ICC/IF, FC	Human, Mouse, Rat
	alpha/beta Synuclein Antibody (YA2999) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2999), targeting alpha/beta Synuclein, with a predicted molecular weight of 14 kDa (observed band size: 18 kDa). alpha/beta Synuclein Antibody (YA2999) can be used for WB, ICC/IF, FC experiment in human, mouse, rat background.

HY-P81612

	gamma Sarcoglycan Antibody (YA1357) BCSG1; Breast cancer specific gene 1 protein; Gamma Synuclein; Persyn; PRSN; SNCG; SR; Synoretin; Synuclein gamma	WB, IHC-P, ICC/IF, IP, FC	Human, Rat
	gamma Sarcoglycan Antibody (YA1357) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1357), targeting gamma Sarcoglycan, with a predicted molecular weight of 13 kDa (observed band size: 16 kDa). gamma Sarcoglycan Antibody (YA1357) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, rat background.